Research Summary: Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.

At the May 2013 Heart Failure Congress a randomized double blind trial was presented showing that CoQ10 caused a 50% decrease in mortality from all cardiac events. As this was the first treatment in over a decade to improve heart failure mortality, the news made headlines in the scientific community. Other CoQ10 studies were bound to follow.

The most recent study to focus on the benefits of CoQ10 for heart health comes from Taiwan, where a group of researchers in Taichung studied the effects of CoQ10 supplementation on patients receiving statins (cholesterol-reducing drugs). Statins have been shown to reduce the biosynthesis of CoQ10, a powerful antioxidant found in nearly all cells of the human body. (CoQ10 works to produce energy in mitochondria, and is the only antioxidant that humans can synthesize.) The researchers investigated the effects that supplementation with CoQ10 might have on patients during statin therapy, particularly its effect on inflammatory markers which are directly correlated with coronary artery disease.